

A 1999312



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:


UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

September 16, 2016

THIS IS TO CERTIFY THAT ANNEXED IS A TRUE COPY FROM THE
RECORDS OF THIS OFFICE OF A DOCUMENT RECORDED ON
JULY 28, 2016.

By Authority of the
Under Secretary of Commerce for Intellectual Property
and Director of the United States Patent and Trademark Office




P. SWAIN
Certifying Officer

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3982605

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT
NATURE OF CONVEYANCE:	Corrective Assignment to correct the ASSIGNEE NAME previously recorded on Reel 038881 Frame 0673. Assignor(s) hereby confirms the ASSIGNEE NAME SHOULD BE CHANGED FROM ALEXO THERAPEUTICS, INC. TO ALEXO THERAPEUTICS INC..
CONVEYING PARTY DATA	
Name	Execution Date
ALEXO THERAPEUTICS INTERNATIONAL	06/08/2016
RECEIVING PARTY DATA	
Name:	ALEXO THERAPEUTICS INC.
Street Address:	951 GATEWAY BOULEVARD
Internal Address:	SUITE 201
City:	SOUTH SAN FRANCISCO
State/Country:	CALIFORNIA
Postal Code:	94080
PROPERTY NUMBERS Total: 14	
Property Type	Number
Application Number:	14971931
Application Number:	62035057
Application Number:	62138257
Application Number:	62138282
Application Number:	62138306
Application Number:	62202772
Application Number:	62202775
Application Number:	62202779
Application Number:	62265887
Application Number:	62276796
Application Number:	62276801
PCT Number:	US2015044528
PCT Number:	US2015044380
PCT Number:	US2016024346
CORRESPONDENCE DATA	
Fax Number:	(650)493-6811
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent</i>	
PATENT	

503935951

REEL: 039502 FRAME: 0461

<i>using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(650) 493-9300
Email:	jhuddleston@wsgr.com, patentdocket@wsgr.com
Correspondent Name:	WILSON SONSINI GOODRICH & ROSATI
Address Line 1:	650 PAGE MILL ROAD
Address Line 4:	PALO ALTO, CALIFORNIA 94304
ATTORNEY DOCKET NUMBER:	47819-700
NAME OF SUBMITTER:	JENNIFFER HUDDLESTON
SIGNATURE:	/Jenniffer C. Huddleston/
DATE SIGNED:	07/28/2016
Total Attachments: 5 source=47819_Corrected_Cover#page1.tif source=47819_Corrected_Cover#page2.tif source=47819_Corrected_Cover#page3.tif source=47819_Corrected_Cover#page4.tif source=47819_Corrected_Cover#page5.tif	

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3913315

SUBMISSION TYPE:	NEW ASSIGNMENT
------------------	----------------

NATURE OF CONVEYANCE:	ASSIGNMENT
-----------------------	------------

CONVEYING PARTY DATA

Name	Execution Date
ALEXO THERAPEUTICS INTERNATIONAL	06/08/2016

RECEIVING PARTY DATA

Name:	ALEXO THERAPEUTICS, INC. ALEXO THERAPEUTICS INC.
Street Address:	951 GATEWAY BOULEVARD
Internal Address:	SUITE 201
City:	SOUTH SAN FRANCISCO
State/Country:	CALIFORNIA
Postal Code:	94080

PROPERTY NUMBERS Total: 14

Property Type	Number
PCT Number:	US2015044528
PCT Number:	US2015044380
Application Number:	62035057
Application Number:	14971931
Application Number:	62138282
Application Number:	62202779
PCT Number:	US2016024346
Application Number:	62138306
Application Number:	62202775
Application Number:	62276801
Application Number:	62138257
Application Number:	62202772
Application Number:	62265887
Application Number:	62276796

CORRESPONDENCE DATA

Fax Number: (650)493-6811

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (650) 493-9300

PATENT
REEL: 039502 FRAME: 0463

PATENT ASSIGNMENT AGREEMENT

This Patent Assignment Agreement (this "Assignment") is effective as of May 25, 2016 (the "Effective Date"), and is entered into between Alexo Therapeutics International, a Cayman Islands company c/o Codan Trust Company (Cayman) Limited, Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman KY1-111, Cayman Islands ("Alexo Cayman") and Alexo Therapeutics Inc., a Delaware corporation, having its place of business at 951 Gateway Boulevard, Ste. 201, South San Francisco, CA 94080, USA ("Alexo USA").

WHEREAS, Alexo Cayman is a biotechnology company engaged in the business of developing protein based therapeutics for the treatment of oncology conditions in humans and Alexo Cayman controls all the rights, titles and interests in the technologies relating thereto;

WHEREAS, Alexo USA has particular capabilities in the area of providing research and development services, possesses suitable facilities and employs professional personnel knowledgeable about and experienced in such work; and

WHEREAS, Alexo Cayman and Alexo USA entered into an Agreement dated May 25, 2016 (the "Agreement") by which Alexo Cayman transferred to Alexo USA title to all intellectual rights owned by Alexo Cayman.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

Subject to the terms of the Agreement, Alexo Cayman hereby sells, assigns, transfers and sets over to Alexo USA and its successors, assigns and other legal representatives all of Alexo Cayman's right, title and interest in and to the patents and patent applications disclosed in Schedule A attached hereto (the "Schedule A Transferred Patent Rights"), including for clarity, the right (a) to claim priority to and from the Schedule A Transferred Patent Rights, (b) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of the Schedule A Transferred Patent Rights, (c) in and to each and every patent issuing or reissuing from any of the foregoing, (d) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing, and (e) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing now or hereafter in effect, for Alexo USA's own use and enjoyment, and for the use and enjoyment of Alexo USA's successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by Alexo Cayman if this assignment and sale had not been made.

Alexo Cayman authorizes and requests the United States Commissioner of Patents and Trademarks and any other applicable government authority to record Alexo USA as the assignee and owner of the Schedule A Transferred Patent Rights, and issue any and all registrations thereon to Alexo USA, as assignee of the entire right, title and interest in, to and under the same, for the sole use and enjoyment of Alexo USA and its successors, assigns or other legal representatives.

Alexo Cayman shall provide to Alexo USA, its successors, assigns or other legal representatives, cooperation and assistance at Alexo USA's request and expense but without additional compensation, (including, without limitation, the execution and delivery of any and all affidavits, declarations, oaths, samples, exhibits, specimens and other documentation as may be reasonably required) in connection with (1) preparation and prosecution of any application within the Schedule A Transferred Patent Rights that Alexo USA may reasonably deem appropriate that may be secured under the laws now or hereafter in effect in the

PATENT
REEL: 039502 FRAME: 0464


United States or any foreign countries; (2) prosecution or defense of any cancellation, opposition, infringement or other proceedings that may arise in connection with any of the Schedule A Transferred Patent Rights, including, without limitation, testifying as to any facts relating to the Schedule A Transferred Patent Rights and this Assignment; (3) enforcement of Alexo USA's rights in any Schedule A Transferred Patent Rights; and (4) implementation, perfection and/or recording of this Assignment.

This Assignment will inure to the benefit of Alexo USA, its successors and assigns, except that Alexo USA may not assign this Assignment without the prior written consent of Alexo Cayman, and will bind Alexo Cayman and its successors and permitted assigns. This Assignment will be governed in all respects, whether as to validity, construction, capacity, performance or otherwise, by the laws of the State of New York without reference to its conflicts of law provisions. If any term or provision of this Assignment is, to any extent or for any reason, held to be invalid or unenforceable, the remainder of this Assignment will not be affected thereby and will be construed as if such invalid or unenforceable provision had never been contained herein or been applicable in such circumstances. This Assignment may not be amended unless mutually agreed upon in writing by both Alexo USA and Alexo Cayman, and no waiver will be effective.

[The remainder of the page left blank intentionally; signature page follows]

IN WITNESS WHEREOF, Alexo Therapeutics International has caused this Assignment to be duly executed as of the date first above written.


Date: June 8, 2016



Corey Goodman, Director
Alexo Therapeutics International

Received and agreed to by Alexo Therapeutics Inc.:

Date: June 8, 2016



Jaume Pons, President
Alexo Therapeutics Inc.

[The remainder of the page left blank intentionally]

Schedule A

Title	Country	Status	App. Number	Filing Date
SIRP-ALPHA VARIANT CONSTRUCTS AND USES THEREOF	PCT	Pending	PCT/US2015/044528	10-Aug-2015
SIRP-ALPHA VARIANT CONSTRUCTS AND USES THEREOF	PCT	Abandoned	PCT/US2015/044380	07-Aug-2015
SIRP-ALPHA VARIANT CONSTRUCTS AND USES THEREOF	Taiwan	Pending	104125902	10-Aug-2015
SIRP-ALPHA VARIANT CONSTRUCTS AND USES THEREOF	United Kingdom	Pending	1522653.3	10-Aug-2015
SIRP-ALPHA VARIANT CONSTRUCTS AND USES THEREOF	USA	Expired	62/035,057	08-Aug-2014
SIRP-ALPHA VARIANT CONSTRUCTS AND USES THEREOF	USA	Pending	14/971,931	16-Dec-2015
CONSTRUCTS HAVING A SIRP-ALPHA DOMAIN OR VARIANT THEREOF	USA	Expired	62/138,282	25-Mar-2015
CONSTRUCTS HAVING A SIRP-ALPHA DOMAIN OR VARIANT THEREOF	USA	Pending	62/202,779	07-Aug-2015
CONSTRUCTS HAVING A SIRP-ALPHA DOMAIN OR VARIANT THEREOF	PCT	Pending	PCT/US2016/024346	25-Mar-2016
CONSTRUCTS HAVING A SIRP-ALPHA DOMAIN OR VARIANT THEREOF	USA	Expired	62/138,306	25-Mar-2015
CONSTRUCTS HAVING A SIRP-ALPHA DOMAIN OR VARIANT THEREOF	USA	Pending	62/202,775	07-Aug-2015
CONSTRUCTS HAVING A SIRP-ALPHA DOMAIN OR VARIANT THEREOF	USA	Pending	62/276,801	08-Jan-2016
COMBINATION THERAPY OF SIRP-ALPHA VARIANTS AND ANTIBODIES	USA	Expired	62/138,257	25-Mar-2015
COMBINATION THERAPY OF SIRP-ALPHA VARIANTS AND ANTIBODIES	USA	Pending	62/202,772	07-Aug-2015
FC CONSTRUCTS WITH REDUCED EFFECTOR FUNCTION	USA	Pending	62/265,887	10-Dec-2015
FC CONSTRUCTS WITH REDUCED EFFECTOR FUNCTION	USA	Pending	62/276,796	08-Jan-2016